Compare Strategy Inc. (MSTR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Twist Bioscience Corp — how do they compare? Strategy Inc. trades at $156.19 (market cap $60.40B), while Twist Bioscience Corp trades at $163.21 (market cap $10.08B). The key difference: Strategy Inc. is far larger — about 6× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and Twist Bioscience Corp for 27 Days on average.
| MSTR | TWST | |
|---|---|---|
Market Cap | $60.40B | $10.08B |
Volume | 23,421,830 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $320.29 | $205.00 |
52-Week Low | $82.31 | $25.45 |
Typical Hold Time | 112 Days | 27 Days |
Enterprise Value | $79.16B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $151.89, down 0.96% on the day, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with a net income margin of -6,102.96% and three consecutive quarterly earnings misses. Despite negative profitability, analyst consensus remains bullish with a $253.36 price target, representing 67% upside potential from current levels. Recent news highlights Citigroup doubling its price target to $240 following a 35% monthly rally.
The outlook remains polarized between technical optimism and fundamental challenges. While technical indicators suggest continued momentum, the company's massive losses and negative cash flow from operations pose significant risks. Investors face the dilemma of strong Wall Street support against deteriorating financial performance, with the stock's fate closely tied to Bitcoin market movements despite being a traditional software company.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
